A new study that analysed the pattern of non-melanoma skin cancer (NMSC) incidence in kidney transplant patients suggests that the increased NMSC risk witnessed in these patients could be related to anti-rejection medications.
Researchers analysed the rates of cancer in 3,821 deceased and living kidney transplant recipients in Ireland. Of these, 3,215 recipients had one transplant, 522 received two, and 84 recipients had three or more kidney transplants.
They found that periods of treatment with a functioning transplant were associated with a higher incidence of NMSC diagnosis than periods of graft failure (adjusted incidence rate ratio [aIRR] 2.19; 95% CI 1.56-3.07; P<.001 the airrs of nmsc fell from ci per patient-years after transplant to in dialysis period following first allograft failure. incidence similarly rose and each subsequent consecutive transplant.>
Writing in JAMA Dermatology, the authors said the findings “serve to highlight the importance of continued cancer surveillance during periods of graft failure in kidney transplant recipients."